Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5757MR)

This product GTTS-WQ5757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14307MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ6093MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ13603MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ1511MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ3238MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ12106MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ2657MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ13124MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW